Products for Research Use Only
RegisterLogin

INX-315

CAT: 0804-HY-162001-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-162001-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research[1].
CAS Number
2745060-92-6
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/inx-315.html
Purity
99.75
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NN1)C2(CCCCC2)N(C1=C3)C4=C3C=NC(NC5=CC=C(S(=O)(N)=O)C=C5)=N4
Molecular Formula
C19H21N7O3S
Molecular Weight
427.48
References & Citations
[1]Dietrich C, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 2023 Dec 4. |[2]Trub A G, et al. INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers[J]. Cancer Research, 2023, 83 (7_Supplement) : 5994-5994.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Chemical Information

CID 162360412

CDK2 Inhibitor INX-315 is an orally bioavailable small molecule inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon oral administration, CDK2 inhibitor INX-315 selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells.

CAS Number2745060-92-6
PubChem CID162360412
IUPAC Name4-[(12-oxospiro[1,3,5,10,11-pentazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-4-yl)amino]benzenesulfonamide
Molecular FormulaC19H21N7O3S
Molecular Weight427.5
XLogP2.4
Topological Polar Surface Area152
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Heavy Atom Count30
Formal Charge0
Complexity759
SMILES
C1CCC2(CC1)C(=O)NNC3=CC4=CN=C(N=C4N23)NC5=CC=C(C=C5)S(=O)(=O)N
InChI
InChI=1S/C19H21N7O3S/c20-30(28,29)14-6-4-13(5-7-14)22-18-21-11-12-10-15-24-25-17(27)19(8-2-1-3-9-19)26(15)16(12)23-18/h4-7,10-11,24H,1-3,8-9H2,(H,25,27)(H2,20,28,29)(H,21,22,23)
InChIKey
KGJVKYSVVOQPDL-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of CID 162360412
CAS: 2745060-92-6
CID: 162360412
Formula: C19H21N7O3S
MW: 427.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight427.5
XLogP32.4
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Exact Mass427.14265873
Monoisotopic Mass427.14265873
Topological Polar Surface Area152 Ų
Heavy Atom Count30
Formal Charge0
Complexity759
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-160182-01INX-P
HY-160181-01INX-SM-3
HY-147119-01INX-SM-6
HY-147179-01INX-SM-56
HY-14334SAM-315
HY-178723AMG-315
HY-117608-01ML 315
HY-19894LTX-315
HY-117608A-01ML 315 (hydrochloride)
HY-W953136CRBN ligand-315

Alternative Products

CatalogName
C01910-01INX-315
A24277-50INX-315 50mg
A24277-100INX-315 100mg
A24277-10INX-315 10mg
A24277-5INX-315 5mg
529117INX 08189
GTR19234320-01INX-P
MBS3600937-01INX-08189
T86724-01INX-SM-3
T77852-01INX-SM-56

Popular Products